Prevention of Loperamide-Induced Constipation in Mice and Alteration of 5-Hydroxytryotamine Signaling by Ligilactobacillus salivarius Li01

Study information

Reviewed Marked as Reviewed by KateRasheed on 2025-6-10

study design

laboratory experiment

Citation

PMID PubMed identifier for scientific articles.

36235735

DOI Digital object identifier for electronic documents.

10.3390/nu14194083

URI Uniform resource identifier for web resources.

Authors

Qiu B, Zhu L, Zhang S, Han S, Fei Y, Ba F, Berglund B, Li L, Yao M

Journal

Nutrients

Year

2022

Keywords:

5-hydroxytryotamine, Ligilactobacillus salivarius Li01, constipation, gut microbiota

Although Ligilactobacillus salivarius Li01 (Li01) has shown much promise in preventing multiple gastrointestinal diseases, the potential of the probiotic in alleviating constipation and the related mechanisms remain unclear. In this study, the effects of Li01 were evaluated in a loperamide-induced constipation mouse model. The results demonstrated that Li01 intervention can relieve constipation symptoms by improving water content, quantity, and morphology of feces and act as an intestinal barrier structure protector. Furthermore, Li01 can modulate gut motility (gastrointestinal transit rate), the fluid transit-associated expression of aquaporins, and the serum parameters vasoactive intestinal peptide, substance P, and somatostatin. Constipation significantly increased the levels of 5-hydroxytryotamine (5-HT) in serum (p < 0.01) and decreased the levels in the intestine (p < 0.001). Due to its function of elevating the expression of tryptophan hydroxylase 1, this was reversed after Li01 treatment. Li01 also promoted the expression of 5-HT receptor 3 and 4, indicating that the 5-HT signaling pathway may play a critical role in the mechanism by which Li01 alleviate constipation symptoms. Additionally, Li01 significantly altered the gut microbiota composition by enhancing the ratio of Firmicutes/Bacteroidetes and increasing the abundance of Rikenellaceae_RC9 genera. Based on the above results, Li01 may have the potential to effectively alleviate constipation by regulating the 5-HT pathway and alteration of the gut microbiota.

Experiment 1

Edit History Delete

Flag for review

Your review change was submittedDuplicate this Experiment Add a new Signature

Reviewed Marked as Reviewed by KateRasheed on 2025-6-10

Curated date: 2025/04/30

Curator: Anne-mariesharp

Revision editor(s): Anne-mariesharp, Montana-D

Subjects

Location of subjects: China

Host species Species from which microbiome was sampled. Contact us to have more species added.: Mus musculus

Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology: Intestine secretion Intestinal juice,Intestinal secretion,Succus entericus,Intestine secretion,intestine secretion

Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology: Constipation Constipation,Costiveness,Dyschezia,constipation

Group 0 name Corresponds to the control (unexposed) group for case-control studies: NC (Normal Control)

Group 1 name Corresponds to the case (exposed) group for case-control studies: LOP (Loperamide-induced constipation)

Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group: Mice that received a daily gavage of 0.4 mL saline buffer for 15 days and 0.2 mL loperamide hydrochloride (10 mg/kg body weight) from the 8th to 15th day to induce constipation.

Group 0 sample size Number of subjects in the control (unexposed) group: 6

Group 1 sample size Number of subjects in the case (exposed) group: 6

Lab analysis

Sequencing type: 16S

16S variable region One or more hypervariable region(s) of the bacterial 16S gene: V3-V4

Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance: Illumina

Statistical Analysis

Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).: relative abundances

Statistical test: ANOVA; Kruskall-Wallis

Significance threshold p-value or FDR threshold used for differential abundance testing (if any): 0.05

MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?: No

Signature 1

Edit History Delete

Flag for review

Your review change was submitted

Reviewed Marked as Reviewed by KateRasheed on 2025-6-10

Curated date: 2025/04/30

Curator: Anne-mariesharp

Revision editor(s): Anne-mariesharp

Source: Figure 5D

Description: Differentially abundant taxon between the NC (Normal Control) group and LOP (Loperamide-induced constipation) group.

Abundance in Group 1: increased abundance in LOP (Loperamide-induced constipation)

NCBI	Quality Control	Links
Muribaculaceae

Revision editor(s): Anne-mariesharp

Signature 2

Edit History Delete

Flag for review

Your review change was submitted

Reviewed Marked as Reviewed by KateRasheed on 2025-6-10

Curated date: 2025/04/30

Curator: Anne-mariesharp

Revision editor(s): Anne-mariesharp

Source: Figure 5E

Description: Differentially abundant taxa between the NC (Normal Control) group and LOP (Loperamide-induced constipation) group.

Abundance in Group 1: decreased abundance in LOP (Loperamide-induced constipation)

NCBI	Quality Control	Links
Alistipes
Lachnospiraceae bacterium NK4A136
Ruminococcus

Revision editor(s): Anne-mariesharp

Experiment 3

Edit History Delete

Flag for review

Your review change was submittedDuplicate this Experiment Add a new Signature

Reviewed Marked as Reviewed by KateRasheed on 2025-6-10

Curated date: 2025/05/02

Curator: Montana-D

Revision editor(s): Montana-D, Ese

Differences from previous experiment shown

Subjects

Group 0 name Corresponds to the control (unexposed) group for case-control studies: LOP (Loperamide-induced constipation)

Group 1 name Corresponds to the case (exposed) group for case-control studies: Li01 (Ligilactobacillus salivarius treatment)

Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group: Mice that received a daily gavage of 0.4 mL Li01 solution (~10^10 CFU/mL) for 15 days and 0.2 mL loperamide hydrochloride (10 mg/kg body weight) from the 8th to 15th day to induce constipation.